Lipid vesicles comprise a lipid bilayer which includes an analog of a cell-surface receptor such as dicetyl phosphate, stearylamine, 6-(5-cholesten-3β-yloxy)hexyl 1-thio-β-L-fucopyranoside, 6-(5-cholesten-3β-yloxy)hexyl 1-thio-β-D-galactopyranoside, 6-(5-cholesten- 3β-yloxy)hexyl 1-thio-a- D-mannopyranoside, 6-(5-cholesten- 3-yloxy)hexyl 2-acetamido-3-deoxy- 1-thio-β-D-galactopyranoside, 6-(5-cholesten- 3β-yloxy)hexyl 6-amino-6-deoxy-1-thio- β-D-galactopyranoside or 6-(5-cholesten- 3p-yloxy)hexyl 6-amino-6-deoxy-1- thio-a-D-mannopyranoside, together with cholesterol, distearoyl phospatidylcholine and an effective amount of a physiologically compatible radioactive tracer or a cytotoxic or therapeutic agent as a part of the vesicles. The vesicles of this invention can be administered to mammalian, including human, hosts and have been found to release the contents of the vesicles in a predetermined manner, and in some cases to be rapidly concentrated in the lymphatic system and/or liver, lungs, or spleen of the host.
脂质囊泡由脂质双分子层组成,其中包括细胞表面受体的类似物,如
磷酸二十六烷基酯、
硬脂胺、6-(
5-胆甾烯-3β-氧基)己基 1-
硫代-β-L-
吡喃
葡萄糖苷、6-(
5-胆甾烯-3β-氧基)己基
1-硫代-β-D-吡喃半乳糖苷、6-(
5-胆甾烯-3β-氧基)己基
1-硫代-β-D-吡喃半乳糖苷、6-(
5-胆甾烯-3β-氧基)己基 1-
硫代-a-D-
吡喃
甘露糖苷、6-(
5-胆甾烯-3-氧基)己基 2-乙酰
氨基-3-脱氧-
1-硫代-β-D-吡喃半乳糖苷、6-(
5-胆甾烯-3β-氧基)己基 6-
氨基-6-脱氧-
1-硫代-β-D-吡喃半乳糖苷或 6-(
5-胆甾烯-3p-氧基)己基 6-
氨基-6-脱氧-1-
硫代-a-D-
吡喃
甘露糖苷,以及
胆固醇、
二硬脂酰磷脂酰
胆碱和有效量的生理相容放射性示踪剂或细胞毒性或治疗剂,作为囊泡的一部分。本发明的囊泡可以给哺乳动物(包括人类)宿主服用,并且发现囊泡中的内容物会以预定的方式释放出来,在某些情况下会迅速集中在宿主的淋巴系统和/或肝、肺或脾中。